Table 1.

Studies performed with dobutamine stress CMR for the detection of CAD by inducible wall motion abnormalities.

Study	Stressor(s)	Number of patients	MR-scanner	Definition of relevant stenosis (%)	Sensitivity (%) with 95%CI	Specificity (%) with 95%CI
Hundley et al., 1999	Dobutamine/Atropin	41	GE 1.5T	>50	83 (86–93)	83 (36–100)
Jahnke et al., 2006	Dobutamine	40	Philips 1.5T	≥50	83 (51–97)	89 (71–97)
Nagel et al., 1999	Dobutamine	172	Philips 1.5T	≥50	86 (78–92)	86 (75–93)
Paetsch et al., 2004	Dobutamine/Atropin	79	Philips 1.5T	>50	89 (77–96)	81 (61–93)
Paetsch et al., 2006	Dobutamine	150	Philips 1.5T	≥50	78 (67–87)	88 (78–94)
Pennell et al., 1992	Dobutamine	25	Picker 0.5T	≥50	91 (71–99)	100 (29–100)
Rerkpattanapipat et al., 2003	Exercise	27	GE 1.5T	>70	79 (49–95)	85 (55–98)
Schalla et al., 2002	Dobutamine	22	Philips 1.5T	>75	81 (54–96)	83 (36–100)
van Rugge et al., 1993	Dobutamine	45	Philips 1.5T	>50	81 (65–92)	100 (63–100)
van Rugge et al., 1994	Dobutamine	39	Philips 1.5T	≥50	91 (76–98)	83 (36–100)
Pooled data	Dobutamine ± Atropin	680		≥50–75	85 (82–90)	86 (81–91)